Page last updated: 2024-10-31

mexiletine and Allodynia

mexiletine has been researched along with Allodynia in 14 studies

Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.

Research Excerpts

ExcerptRelevanceReference
"To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing."9.11Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004)
"The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine."7.78Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012)
"Static and dynamic allodynia occurred in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve."5.35Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E; Tanimoto-Mori, S, 2009)
"Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C."5.31Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001)
"To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing."5.11Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004)
"The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine."3.78Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012)
" In this study, we investigated the effects of M58373 on substance P release from sensory neurons in vitro and pain behaviors/responses in rats, compared with mexiletine."3.73Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. ( Akada, Y; Amano, K; Fukudome, Y; Itoh, M; Ogawa, S; Yamamoto, I; Yamasaki, F, 2006)
"Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i."3.69The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997)
"The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test."1.43Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016)
"Static and dynamic allodynia occurred in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve."1.35Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E; Tanimoto-Mori, S, 2009)
"Pretreatment with mexiletine, at doses of 3, 10 and 30 mg/kg, i."1.33Effect of mexiletine on vincristine-induced painful neuropathy in mice. ( Kamei, J; Nozaki, C; Saitoh, A, 2006)
"Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C."1.31Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's9 (64.29)29.6817
2010's3 (21.43)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Shinozuka, T1
Kobayashi, H1
Suzuki, S1
Tanaka, K1
Karanjule, N1
Hayashi, N1
Tsuda, T1
Tokumaru, E1
Inoue, M1
Ueda, K1
Kimoto, H1
Domon, Y1
Takahashi, S1
Kubota, K1
Yokoyama, T1
Shimizugawa, A1
Koishi, R1
Fujiwara, C1
Asano, D1
Sakakura, T1
Takasuna, K1
Abe, Y1
Watanabe, T1
Kitano, Y1
Yamamoto, S1
Kawashiri, T1
Higuchi, H1
Tsutsumi, K1
Ushio, S1
Kaname, T1
Shirahama, M1
Egashira, N1
Matsuura, W1
Harada, S1
Tokuyama, S1
Nakazato-Imasato, E1
Tanimoto-Mori, S1
Kurebayashi, Y1
Ito, S1
Tajima, K1
Nogawa, M1
Inoue, N1
Kyoi, T1
Takahashi, Y1
Sasagawa, T1
Nakamura, A1
Kotera, T1
Ueda, M1
Yamashita, Y1
Banno, K1
Attal, N1
Rouaud, J1
Brasseur, L1
Chauvin, M1
Bouhassira, D1
Kamei, J4
Nozaki, C1
Saitoh, A1
Akada, Y1
Ogawa, S1
Amano, K1
Fukudome, Y1
Yamasaki, F1
Itoh, M1
Yamamoto, I1
Jett, MF1
McGuirk, J1
Waligora, D1
Hunter, JC1
Zushida, K2
Wu, WP1
Nordmark, J1
Wiesenfeld-Hallin, Z1
Xu, XJ1
Sasaki, M1
Morita, K1
Tanaka, S1
Laird, JM1
Carter, AJ1
Grauert, M1
Cervero, F1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267]Phase 329 participants (Actual)Interventional2014-08-01Completed
Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394]Phase 1/Phase 226 participants (Actual)Interventional2017-09-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Cumulative Dose of Oxaliplatin

The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks

Interventionmg (Mean)
Placebo + FOLFOX1161.8
Lidocaine + FOLFOX1294.8

Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time

"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks

,
Interventionscore on a scale*days (Mean)
pain AUCunpleasantness AUC
Lidocaine + FOLFOX9.525.4
Placebo + FOLFOX16.433.1

Changes in NPSI Score.

Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks

,
Interventionscore on a scale (Median)
6 weeks visit12 weeks visitlast follow-up visit
Lidocaine + FOLFOX0013.5
Placebo + FOLFOX003.0

CIPN Score on EORTC QLQ-CIPN20

"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks

,
Interventionscore on a scale (Median)
1234-36 weeks
Lidocaine + FOLFOX437.0
Placebo + FOLFOX217.0

Trials

1 trial available for mexiletine and Allodynia

ArticleYear
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
    Neurology, 2004, Jan-27, Volume: 62, Issue:2

    Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp

2004

Other Studies

13 other studies available for mexiletine and Allodynia

ArticleYear
Discovery of DS-1971a, a Potent, Selective Na
    Journal of medicinal chemistry, 2020, 09-24, Volume: 63, Issue:18

    Topics: Analgesics; Animals; Drug Discovery; Female; Humans; Hyperalgesia; Macaca fascicularis; Male; Mice;

2020
Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats.
    Journal of pharmacological sciences, 2015, Volume: 129, Issue:1

    Topics: Administration, Ophthalmic; Analgesics; Animals; Antineoplastic Agents; Axons; Bortezomib; Duloxetin

2015
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:5

    Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico

2016
Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats.
    The Journal of veterinary medical science, 2009, Volume: 71, Issue:7

    Topics: Analgesics; Animals; Chronic Disease; Constriction, Pathologic; Dose-Response Relationship, Drug; Hy

2009
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 342, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Int

2012
Effect of mexiletine on vincristine-induced painful neuropathy in mice.
    European journal of pharmacology, 2006, Apr-24, Volume: 536, Issue:1-2

    Topics: Animals; Arginine; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibi

2006
Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
    European journal of pharmacology, 2006, May-01, Volume: 536, Issue:3

    Topics: Analgesics; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Formaldehyde; Ganglia, Spina

2006
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
    Pain, 1997, Volume: 69, Issue:1-2

    Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr

1997
[Antinociceptive effects of the enantiomorphs and its main metabolite in streptozotocin-induced diabetic mice].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2000, Volume: 20, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; beta-Endorphin; Diabetes Mellitus, Experimental; Diabetic Neuropath

2000
Effect of mexiletine on thermal allodynia and hyperalgesia in diabetic mice.
    Japanese journal of pharmacology, 2000, Volume: 84, Issue:1

    Topics: Analgesics; Animals; Capsaicin; Diabetes Complications; Drug Interactions; Hot Temperature; Hyperalg

2000
Lack of stereoselectivity for the antiallodynic effect of mexiletine in spinally injured rats.
    European journal of pain (London, England), 2000, Volume: 4, Issue:4

    Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Drug Evaluation, Preclinical; Female;

2000
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.
    Japanese journal of pharmacology, 2001, Volume: 86, Issue:3

    Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Enzyme Activators; Enzyme Inhibitors; Hyperalgesia;

2001
Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats.
    British journal of pharmacology, 2001, Volume: 134, Issue:8

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzomorphans

2001